Advertisement

Annals of Surgical Oncology

, Volume 7, Issue 1, pp 51–54 | Cite as

Sentinel Node Biopsies in Melanoma Patients: A Protocol for Accurate, Efficient, and Cost-Effective Analysis by Preselection for Immunohistochemistry on the Basis of Tyr-PCR

  • D. van der Velde-Zimmermann
  • M. E. I. Schipper
  • R. A. de Weger
  • A. Hennipman
  • I. H. M. Borel Rinkes
Original Article

Abstract

Background: Immunohistochemistry (IHC) of serial sectioning is considered the gold standard for detection of melanoma activity in sentinel node (SN) biopsies. However, this is cost and labor intensive. In contrast, tyrosinase reverse transcription-polymerase chain reaction (RT-PCR) is simple and quick, but it is hampered by its extreme sensitivity. This study was performed to test whether a strategy that combines the two methods, using tyrosinase RT-PCR to preselect nodes for IHC, could be accurate and cost effective.

Methods: In 36 patients, SNs were identified by scintigraphy and patent blue uptake. Of each SN, one cross section was analyzed first by hematoxylin and eosin staining. Next, all nodes were examined by serial sectioning and IHC of one-half and tyrosinase RT-PCR of the other. Before comparison, all results were documented in a blinded manner. Material costs and workload estimates were noted per SN.

Results: Fifty-five SNs were retrieved from the 36 patients. Hematoxylin and eosin staining of the first cross section revealed tumor positivity in 3 patients (6 SN). Tyrosinase RT-PCR was positive in 11 of the remaining 33 patients (19 of 49 SN). Of these same 11 patients, only 5 were shown to have tumor-positive SNs by using IHC on serial sections (7 SN). All these nodes had been positive for tyrosinase on PCR. For IHC, an average of 40 sections were prepared and examined per SN at a cost of $200(U.S.)/SN. In contrast, routine tyrosinase RT-PCR costs $37(U.S.)/SN, and takes 5% of the time necessary for IHC. A strategy including hematoxylin and eosin staining on the first cross section, followed by tyrosinase RT-PCR on half of each negative (half) node, could preselect nodes to be taken through serial sectioning. In these series, such a strategy would have prevented serial sectioning and IHC of 30 SN from 22 patients. Apart from a considerable gain in efficiency, this would have reduced material costs by a minimum of $6000 (U.S.). This iscrepancy would be even higher if work intensity of analysts and pathologists were considered.

Conclusions: In routine analysis of SN biopsies in melanoma patients, tyrosinase RT-PCR can be used effectively to preselect nodes for further IHC of serial sections. This method seems both time and cost effective.

Keywords

Melanoma Sentinel node analysis Tyrosinase RT-PCR Immunohistochemistry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Goydos JS, Ravikumar TS, Germino FJ, Yudd A, Bancila E. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 1998;187:182–188.Google Scholar
  2. 2.
    Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol 1993;2:137–143.CrossRefGoogle Scholar
  3. 3.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.PubMedGoogle Scholar
  4. 4.
    Godellas CV, Berman CG, Lyman G, et al. The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. Am Surg 1995;61:97–101.Google Scholar
  5. 5.
    Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227–1229.Google Scholar
  6. 6.
    van der Velde-Zimmermann D, Roijers JFM, Bouwens-Rombouts A, et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759–764.Google Scholar
  7. 7.
    Battayani Z, Grob JJ, Xerri L, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995;131:443–447.Google Scholar
  8. 8.
    Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995;72:155–159.Google Scholar
  9. 9.
    Joseph E, Messina J, Glass FL, et al. Radioguided surgery for the ultrastaging of the patient with melanoma (see Comments). Cancer J Sci Am 1997;3:341–345.Google Scholar
  10. 10.
    Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998;16:1760–1769.Google Scholar
  11. 11.
    Keilholz U, Willhauck M, Rimoldi D, et al. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer 1998;34:750–753.Google Scholar
  12. 12.
    Dalerba P, Ricci A, Russo V, et al. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigenspecific vaccination strategies. Int J Cancer 1998;77:200–204.Google Scholar
  13. 13.
    Farthmann B, Eberle J, Krasagakis K, et al. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 1998;110:263–267.Google Scholar
  14. 14.
    Blaheta HJ, Schittek B, Breuninger H, et al. Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 1998;79:318–323.Google Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2000

Authors and Affiliations

  • D. van der Velde-Zimmermann
    • 1
  • M. E. I. Schipper
    • 2
  • R. A. de Weger
    • 2
  • A. Hennipman
    • 1
  • I. H. M. Borel Rinkes
    • 1
    • 3
  1. 1.Departments of SurgeryUniversity HospitalUtrechtThe Netherlands
  2. 2.Departments of PathologyUniversity HospitalUtrechtThe Netherlands
  3. 3.Department of SurgeryUniversity HospitalUtrechtThe Netherlands

Personalised recommendations